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Metabolic markers associated 
with insulin resistance predict type 2 diabetes 
in Koreans with normal blood pressure or 
prehypertension
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Abstract 
Background: Questions remain as to the association between essential hypertension and increased incidence 
of type 2 diabetes (T2DM). The premise of this analysis is that insulin resistance/compensatory hyperinsulinemia 
is a major predictor of T2DM, and the greater the prevalence of insulin resistance within any population, normo‑
tensive or hypertensive, the more likely T2DM will develop. The hypothesis to be tested is that surrogate estimates 
of insulin resistance will predict incident T2DM to a significant degree in persons with normal blood pressure or 
prehypertension.
Methods: Analysis of data from a population‑based survey of 10, 038 inhabitants of rural and urban areas of 
Korea, ≥40 years‑old, initiated in 2001, with measures of demographic and metabolic characteristics at baseline and 
8‑years later. Participants were classified as having normal blood pressure or prehypertension, and three simple mani‑
festations of insulin resistance related to the pathophysiology of T2DM used to predict incident T2DM: (1) glycemia 
(plasma glucose concentration 2‑hour after 75 g oral glucose challenge = 2‑hour PG); (2) hyperinsulinemia (plasma 
insulin concentration 2‑hour after 75 g oral glucose challenge = 2‑hour PI); and (3) dyslipidemia (ratio of fasting 
plasma triglyceride/high/density lipoprotein cholesterol concentration = TG/HDL‑C ratio).
Results: Fully adjusted hazard ratios (HR, 95 % CI) for incident T2DM were highest (P < 0.001) in the quartile of 
individuals with the highest 2‑hour PG concentrations, ranging from 5.84 (3.37–10.1) in women with prehyperten‑
sion to 12.2 (7.12–21.00) in men with normal blood pressure. T2DM also developed to a significantly greater degree 
in subjects within the highest quartile of TG/HDL‑C ratios, with HRs varying from 2.91 (1.63–2.58) in women with 
prehypertension (P < 0.001) to 1.77 (1.12–2.81, P < 0.05) in men with prehypertension. The least predictive index of 
insulin resistance was the 2‑hour PI concentration. Subjects with normal blood pressure in the highest quartile of 
2‑hour PI concentrations were significantly associated with incident T2DM, with HRs of 1.5 (1.02–2.20, P = 0.25) and 
2.02 (1.35–3.02, P < 0.001), in men and women, respectively. Finally, incidence of T2DM in the highest quartile was 
somewhat greater in patients with prehypertension, irrespective of predictor.
Conclusions: Metabolic variables associated with insulin resistance (glycemia, insulinemia, and dyslipidemia) predict 
the development of T2DM in patients with either normal blood pressure or prehypertension.
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Background
In a recent publication, Emdin and colleagues pointed-
out that despite biological rationale for a relationship 
between elevated blood pressure and incident type 2 dia-
betes (T2DM), 12 of 30 cohort studies reviewed could 
not identify evidence of this association. Furthermore, 
the remaining 18 studies “reported a considerably vari-
able strength of association [1]”. In an effort to obtain a 
more definitive view of the putative association between 
elevated blood pressure and T2DM, they analyzed medi-
cal records of 4.1 million individuals, free of hyperten-
sion and T2DM, in a U.K. primary care setting, as well 
as performing a meta-analysis of existing prospective 
studies. The results of their analysis documented a sig-
nificant association between elevations of blood pressure 
and T2DM, and concluded that “further investigation is 
needed to determine whether this association is causal.”
The association between elevated blood pressure and 
T2DM is not limited to inhabitants of the U.K., and 
results of the recent Korean Genome and Epidemio-
logical Study have demonstrated that this relationship 
also exists in patients with prehypertension [2]. Assum-
ing the presence of an association between elevations 
in blood pressure and T2DM, it remains to be seen, as 
pointed out by Emdin, et al. [1], if the two abnormalities 
are causally related. The overall hypothesis underlying 
this analysis is that the association between hypertension 
and T2DM is causal in nature, and related to the role of 
insulin resistance as a major risk factor in the genesis of 
both hypertension and T2DM [3–5]. Put most simply, 
insulin resistance is a predictor of T2DM [3, 4], and the 
greater the prevalence of this defect in a population [5], 
the more at risk of T2DM they will be. The more specific 
hypothesis underlying this analysis is that surrogate esti-
mates of insulin resistance will predict incident T2DM 




The Korean Genome and Epidemiology Study [2], a pop-
ulation-based prospective cohort study, was initiated to 
investigate prevalence in Korea of risk factors for chronic 
disease, as well as incident disease. The survey began in 
2001–2002, included 10,038 participants  ≥40  years of 
age, and follow-up examinations were performed every 
2 years. Specimens have been collected from residents in 
both rural (Anseong) and urban (Ansan) areas. Baseline 
and 8-year follow-up data were obtained from the Center 
for Genome Science in the National Institute of Health, 
Korea. Details of the present cohort have been described 
elsewhere [6]. Of the initial cohort, complete data were 
available on 5697 participants classified at baseline as 
having normal blood pressure (n  =  3930) or prehyper-
tension (n =  1767), and analysis of these data form the 
substance of this report (Fig. 1). The study protocol was 
approved by the Institutional Review Board of the Korea 
Centers for Disease Control and Prevention, and written 
informed consent was obtained from all participants.
Demographic and metabolic measurements
Waist circumference (WC) was measured at the mid-
point between the ribs and the iliac crest in the standing 
position. Body weight and height were measured to the 
nearest 0.1 kg and 0.1 cm, with body mass index (BMI) 
calculated as weight (kg) divided by height (m2). BP was 
measured after a 5 min rest period in the supine position, 
with measurements taken at least twice at 30-s intervals 
and averaged. Blood samples were collected after at least 
an 8 h fast. Plasma glucose (PG), total cholesterol, high-
density lipoprotein cholesterol (HDL-C), and triglyceride 
(TG) concentrations were measured enzymatically, and 
low-density lipoprotein cholesterol concentrations esti-
mated by the Friedwald formula [7] Plasma insulin (PI) 
concentrations were measured by radioimmunoassay and 
hemoglobin A1C (HbA1C) concentrations by high-per-
formance liquid chromatography.
Definition of diabetes mellitus and hypertension
Diabetes mellitus was diagnosed according to criteria of 
the American Diabetes Association as either a fasting 
PG ≥126 mg/dL, a PG concentration ≥200 mg/dL 2-hours 
after an oral glucose challenge, an HbA1C ≥6.5 %, or use of 
an oral hypoglycemic agent [8]. Participants were classified 
Fig. 1 Study flow chart showing subjects screened, included and 
followed up
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according to the Seventh Report of the Joint National Com-
mittee Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure [9] as having normal blood pressure 
(<120  mm  Hg systolic and <80  mm  Hg diastolic) or pre-
hypertension (120–139 mm Hg systolic or 80–89 mm Hg 
diastolic). The 1453 participants considered to have hyper-
tension at baseline, based upon an elevated blood pressure 
(≥40 mm Hg systolic or ≥90 mm Hg diastolic) or use of 
blood pressure-lowering medication, were excluded from 
further analysis to avoid the possible adverse effects of 
hypertension-related peripheral vascular disease on insulin 
resistance as contributing to their 21 % incidence of T2DM.
Surrogate estimates of insulin resistance
The ability of three different manifestations of insulin 
resistance to identify enhanced risk of T2DM in partici-
pants with either normal BP or prehypertension at base-
line was evaluated.
1. 2-hour PG: PG concentration 2-hours after an oral 
glucose challenge to estimate the degree to which 
the overall glycemic status has decompensated in the 
face of a decrease in insulin action.
2. 2-hour PI: PI concentration 2-hours after an oral 
glucose challenge to estimate compensatory insulin 
response in the face of insulin resistance [10, 11].
3. Fasting plasma TG/HDL-C ratio: lipid factors associ-
ated with insulin resistance, known to be significantly 
correlated with insulin resistance and adverse clinical 
outcome [12–15].
Statistical analysis
Distribution testing for normality was performed using 
the Shapiro–Wilk test, with the data log-transformed to 
obtain normalized distributions. The baseline charac-
teristics of subjects were expressed as mean ± S.D., or 
geometric means with 95  % confidence intervals (CIs). 
Differences between groups were compared by one-
way analysis of variance for continuous variables and χ2 
tests for categorical variables. The geometric means of 
log-transformed variables were back-transformed for 
ease of interpretation and reported with their 95 % CIs. 
Diabetes incidence rate was calculated per 1000 person-
years for 2-hour PG, 2-hour PI, and plasma TG/HDL-C 
concentration ratio. Cox proportional hazards models 
were used to analyze time at risk and the association, 
HOMA-IR, 2-hour insulin, and TG/HDL-C ratio, and 
reported as hazard ratios (HRs) and 95  % CIs. Partici-
pants with 1st quartile of each variable at baseline were 
considered the reference group. Values of P < 0.05 were 
considered statistically significant. All data were ana-
lyzed using SPSS software (version 21.0; SPSS, Chicago, 
IL, USA).
Results
Baseline demographic and metabolic characteristics 
in the total experimental population are presented in 
Table  1. In addition, Table  1 contains comparison of 
these experimental variables in the normal and prehy-
pertension subgroups. These data indicate that patients 
with prehypertension were older, with higher values for 
Table 1 Comparison of baseline characteristics among participants with normal blood pressure and prehypertension
The data are expressed as mean ± standard deviation. Statistical differences between groups were compared with one-way ANOVA
BMI body mass index, WC waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, 2-hour PG plasma glucose 
2-hours post-glucose challenge, FPI fasting insulin, 2-hour PI plasma insulin 2-hours post-glucose challenge, HOMA-IR homeostatic model for insulin resistance, TC 
total cholesterol, HDL-C high-density-lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglyceride
Variable All (n = 5697) Normal BP (n = 3930) Prehypertension (n = 1767) P value
Age (year) 50.6 ± 8.5 49.3 ± 7.9 53.6 ± 8.9 <0.001
BMI (kg/m2) 24.1 ± 3.0 23.9 ± 2.9 24.6 ± 3.1 <0.001
WC (cm) 81.1 ± 8.4 80.0 ± 8.2 83.6 ± 8.5 <0.001
SBP (mmHg) 110.4 ± 12.5 104.3 ± 9.0 124.1 ± 7.2 <0.001
DBP (mmHg) 71.3 ± 9.1 67.5 ± 7.7 79.8 ± 5.6 <0.001
FPG (mg/dL) 82.4 ± 8.3 81.9 ± 8.1 83.5 ± 8.7 <0.001
2‑hour PG (mg/dL) 112.0 ± 29.5 111.2 ± 28.9 113.7 ± 30.9 0.003
FPI (μIU/mL) 7.34 ± 4.83 7.18 ± 4.67 7.71 ± 5.15 <0.001
2‑hour PI (μU/mL) 26.4 ± 24.6 26.2 ± 24.0 26.8 ± 25.9 0.354
HOMA‑IR 1.50 ± 1.01 1.46 ± 0.97 1.59 ± 1.10 <0.001
Hemoglobin A1C (%) 5.52 ± 0.34 5.50 ± 0.33 5.57 ± 0.35 <0.001
TC (mg/dL) 188.0 ± 33.2 186.3 ± 32.4 191.7 ± 34.8 <0.001
HDL‑C (mg/dL) 45.3 ± 9.9 45.3 ± 9.7 45.4 ± 10.2 0.845
LDL‑C (mg/dL) 114.5 ± 30.6 114.1 ± 29.6 115.5 ± 32.7 0.105
TG (mg/dL) 140.6 ± 64.6 134.5 ± 61.5 154.1 ± 69.0 <0.001
TG/HDL‑C 3.38 ± 2.04 3.23 ± 1.95 3.70 ± 2.19 <0.001
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body mass index and waist circumference, and higher 
blood pressures. With the exception of the 2-hour 
plasma insulin, high-density lipoprotein cholesterol, and 
low-density lipoprotein concentration, the values were 
all other metabolic variables were higher in those with 
prehypertension.
Table  2 presents the sex-stratified risk for incident 
T2DM in normal subjects and patients with prehyper-
tension divided into quartiles of the on the basis of their 
2-hour PG concentration. Incident T2DM was greatest 
in the highest quartile of those with prehypertension in 
both men (43 vs. 31 %) and women (37 vs. 25 %). In gen-
eral, the higher the quartile, the greater the fully adjusted 
HR, varying in quartile 4 from 5.84 (3.37–10.1) in prehy-
pertensive women to 12.2 (7.12–21.0) in men with nor-
mal blood pressure (all P < 0.001).
Table 3 contains a similar comparison, but in this case 
the quartiles were created as a function of the magnitude 
of the TG/HDL-C ratio. Incident T2DM was again great-
est in the highest quartile of those with prehypertension 
in both men (24 vs. 18 %) and women (24 vs. 16 %). When 
compared to the 2-hour PG, the actual values of the HRs 
were lower when the TG/HDL-C ratio was used to pre-
dict incident T2DM. However, the HRs in the upper 
quartile and incident T2DM remained statistically sig-
nificantly associated in the fully adjusted model in both 
experimental groups and in men and women.
Table  4 depicts the sex-stratified risk for incident 
T2DM when persons with normal blood pressure and 
patients with prehypertension were stratified into quar-
tiles on the basis of their 2-hour PI concentration. As 
before, incident T2DM occurred more commonly in men 
(26 vs. 18 %) and women (20 vs. 15 %) with prehyperten-
sion. Although this manifestation of insulin resistance 
predictor was the least powerful in identifying incident 
T2DM, the fully adjusted model still detected a signifi-
cant trend (P  <  0.05) between magnitude of 2-hour PI 
and incident T2DM in both populations and n men and 
women. Furthermore, the HR of the quartile with the 
highest 2-hour PI concentration (quartile 4) was still 
Table 2 Sex-stratified risk for  incident diabetes by  quartile of  2-hour plasma glucose among  participants with  normal 
blood pressure and prehypertension
Model 1: adjusted for age
Model 2: adjusted for the variables in model 1 and body mass index, family history of diabetes (yes or no), education (less than high school, high school or equivalent, 
or college or above), alcohol use (current or non-current), and smoking status (current or non-current)
* P < 0.05, ** P < 0.001
Number 
at risk
Diabetes cases Unadjusted Model 1 Model 2
HR (95 % CI) P for trend HR (95 % CI) P for trend HR (95 % CI) P for trend
Normal BP
 Men
  Quartile 1 462 15 1 (reference) <0.001 1 (reference) <0.001 1 (reference) <0.001
  Quartile 2 428 29 2.08 (1.12–3.88)* 2.08 (1.12–3.88)* 2.07 (1.11–3.86)*
  Quartile 3 439 45 3.20 (1.78–5.74)** 3.20 (1.78–5.73)** 3.28 (1.82–5.90)**
  Quartile 4 443 138 11.8 (6.95–20.2)** 11.8 (6.94–20.2)** 12.2 (7.12–21.0)**
 Women
  Quartile 1 555 18 1 (reference) <0.001 1 (reference) <0.001 1 (reference) <0.001
  Quartile 2 562 23 1.32 (0.71–2.45) 1.30 (0.70–2.40) 1.27 (0.68–2.35)
  Quartile 3 521 41 2.52 (1.45–4.39)* 2.45 (1.41–4.27)* 2.24 (1.28–3.91)*
  Quartile 4 517 130 9.04 (5.52–14.8)** 8.76 (5.35–14.4)** 8.10 (4.92–13.3)**
Prehypertension
 Men
  Quartile 1 238 12 1 (reference) <0.001 1 (reference) <0.001 1 (reference) <0.001
  Quartile 2 246 21 1.66 (0.82–3.38) 1.68 (0.83–3.42) 1.60 (0.79–3.26)
  Quartile 3 235 36 3.26 (1.70–6.27)** 3.21 (1.67–6.17)** 3.09 (1.60–5.95)*
  Quartile 4 230 99 10.4 (5.72–19.0)** 10.5 (5.75–19.1)** 9.96 (5.44–18.2)**
 Women
  Quartile 1 213 16 1 (reference) <0.001 1 (reference) <0.001 1 (reference) <0.001
  Quartile 2 197 10 0.71 (0.32–1.57) 0.72 (0.33–1.58) 0.70 (0.32–1.54)
  Quartile 3 209 28 1.84 (0.99–3.40) 1.83 (0.99–3.39) 1.78 (0.96–3.30)
  Quartile 4 199 73 6.16 (3.58–10.6)** 6.13 (3.56–10.5)** 5.84 (3.37–10.1)**
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significantly associated to the development of T2DM in 
men (1.50, 1.02–2.21) and women (2.02, 1.35–3.02) with 
normal blood pressure.
Quartiles of all variables, baseline characteristics 
according to diabetes status at follow-up and risk for 
incident diabetes by quartile of HOMA-IR are shown in 
Additional file 1.
Discussion
This analysis was based on the premise that the greater 
the prevalence of insulin resistance within any diagnos-
tic category, the more likely the incident rate of T2DM 
will increase. In other words, the fundamental ques-
tion related to the likelihood of developing T2DM is not 
whether a person has a normal blood pressure or prehy-
pertension, but whether or not they are insulin resistant. 
Before discussing the findings that support this hypoth-
esis, it seems crucial to address the methods used to 
evaluate the association between insulin resistance and 
T2DM in the two experimental groups. Insulin resistance 
in nondiabetic persons is associated with increased gly-
cemia, hyperinsulinemia, and dyslipidemia, irrespective 
of whether they have normal blood pressure [16] or pre-
hypertension [17]. Many other metabolic markers have 
been used to identify insulin resistance in nondiabetic 
persons, employing more sophisticated approaches [18–
22]. For example, HOMA-IR [18] is commonly used in 
population-based studies to provide a surrogate estimate 
of insulin resistance. However, HOMA-IR is a calculated 
value that combines within mathematical formula meas-
urements of PI and PG concentrations. Since the 2-hour 
PG was being used in the analysis as one of the variables 
associated with insulin resistance, we thought it prudent 
not to use HOMA-IR which also includes a measurement 
of PG. Faced with the myriad associations between insulin 
resistance and multiple metabolic markers [18–22], it was 
decided to use the simplest available measurements of the 
three cardinal manifestations of insulin resistance in non-
diabetic individuals: glycemia (2-hour PG), hyperinsuline-
mia (2-hour PI), and dyslipidemia (TG/HDL-C ratio).
Table 3 Sex-stratified risk for incident diabetes by quartile of TG/HDL-C among participants with normal blood pressure 
and prehypertension
Model 1: adjusted for age
Model 2: adjusted for the variables in model 1 and fasting plasma glucose, body mass index, family history of diabetes (yes or no), education (less than high school, 
high school or equivalent, or college or above), alcohol use (current or non-current), and smoking status (current or non-current)





Unadjusted Model 1 Model 2
HR (95 % CI) P for trend HR (95 % CI) P for trend HR (95 % CI) P for trend
Normal BP
 Men
  Quartile 1 443 39 1 (reference) <0.001 1 (reference) <0.001 1 (reference) <0.001
  Quartile 2 444 47 1.15 (0.75‑1.76) 1.16 (0.76‑1.77) 1.18 (0.77‑1.81)
  Quartile 3 444 61 1.53 (1.02‑2.28)* 1.54 (1.03‑2.30)* 1.54 (1.02‑2.32)*
  Quartile 4 443 82 2.16 (1.47‑3.16)** 2.21 (1.51‑3.23)** 2.08 (1.39‑3.12)**
 Women
  Quartile 1 539 32 1 (reference) <0.001 1 (reference) <0.001 1 (reference) <0.001
  Quartile 2 539 44 1.43 (0.91–2.27) 1.41 (0.89‑2.23) 1.55 (0.98‑2.46)
  Quartile 3 539 49 1.60 (1.02–2.51)* 1.53 (0.98‑2.41) 1.63 (1.03‑2.57)*
  Quartile 4 539 88 3.00 (1.97–4.47)** 2.72 (1.80‑4.12)* 2.58 (1.70‑3.94)**
Prehypertension
 Men
  Quartile 1 237 37 1 (reference) <0.001 1 (reference) <0.001 1 (reference) <0.001
  Quartile 2 237 37 0.92 (0.58–1.45) 0.93 (0.59–1.46) 0.96 (0.60–1.54)
  Quartile 3 238 37 0.98 (0.62–1.55) 1.01 (0.64–1.59) 1.03 (0.63–1.68)
  Quartile 4 237 57 1.54 (1.02–2.33)* 1.65 (1.09–2.50)* 1.77 (1.12–2.81)*
 Women
  Quartile 1 206 16 1 (reference) <0.001 1 (reference) <0.001 1 (reference) <0.001
  Quartile 2 203 22 1.39 (0.73–2.65) 1.39 (0.73–2.64) 1.35 (0.70–2.59)
  Quartile 3 205 41 2.78 (1.56 –4.96)* 2.76 (1.55–4.92)* 2.66 (1.47–4.79)*
  Quartile 4 204 48 3.23 (1.83–5.69)** 3.18 (1.80–5.62)** 2.91 (1.63–5.18)**
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Within the potential limitations of the markers selected 
for this analysis, the results in Tables  2, 3, 4 provide 
experimental support for the hypothesis that the more 
insulin resistant an individual, whether they had nor-
mal blood pressure or prehypertension, the greater their 
risk of developing T2DM. Specifically, the greater was 
the magnitude of the manifestations of insulin resist-
ance, whether it is glycemia, hyperinsulinemia, or dys-
lipidemia, the more likely the development of T2DM. 
Furthermore, these general findings obtained irrespective 
of sex and clinical diagnosis.
Although the findings in Tables 2, 3, 4 are comparable 
in that manifestations of insulin resistance were signifi-
cantly associated with incident T2DM in both experi-
mental populations, it should be noted that metabolic 
characteristics of insulin resistance were accentuated in 
patients with prehypertension [Table  1]. By selection, 
blood pressure was also elevated in those with prehyper-
tension. These considerations bring into focus the ques-
tion of causality raised by Emdin and colleagues [1]: does 
elevated blood pressure, per se, increase risk of T2DM, or 
do abnormalities that increase risk of hypertension also 
increase risk of T2DM? This question cannot be answered 
by the current data, but a strong biological argument can 
be made in support of the second alternative. For exam-
ple, normotensive, first-degree relatives of patients with 
high blood pressure are insulin resistant when com-
pared to normotensive individuals without a family his-
tory of hypertension [23–25], and surrogate markers of 
insulin resistance predict incident hypertension [26, 27]. 
Finally, there is considerable evidence that resistance to 
insulin-mediated glucose uptake is increased in patients 
with essential hypertension when compared to appropri-
ate control groups [28–30]. On the other hand, there are 
important differences in the relationship between insulin 
resistance and T2DM as compared to its relationship to 
hypertension [5]. Thus, the overwhelming majority of 
patients with T2DM are insulin resistant, whereas only 
approximately 50  % of patients with essential hyperten-
sion, treated or untreated, are insulin resistant [31], and 
Table 4 Sex-stratified risk for incident diabetes by quartile of 2 h plasma insulin among participants with normal blood 
pressure and prehypertension
Model 1: adjusted for age
Model 2: adjusted for the variables in model 1 and fasting plasma glucose, body mass index, family history of diabetes (yes or no), education (less than high school, 
high school or equivalent, or college or above), alcohol use (current or non-current), and smoking status (current or non-current)





Unadjusted Model 1 Model 2
HR (95 % CI) P for trend HR (95 % CI) P for trend HR (95 % CI) P for trend
Normal BP
 Men
  Quartile 1 446 43 1 (reference) <0.001 1 (reference) <0.001 1 (reference) <0.001
  Quartile 2 443 48 1.06 (0.70–1.60) 1.07 (0.71–1.61) 1.09 (0.72–1.64)
  Quartile 3 440 57 1.31 (0.88–1.94) 1.34 (0.90–1.99) 1.27 (0.85–1.90)
  Quartile 4 443 79 1.90 (1.31–2.76)* 1.94 (1.34–2.82)* 1.50 (1.02–2.21)*
 Women
  Quartile 1 541 36 1 (reference) <0.001 1 (reference) <0.001 1 (reference) <0.001
  Quartile 2 542 41 1.13 (0.72–1.76) 1.14 (0.73–1.79) 1.16 (0.74–1.82)
  Quartile 3 543 56 1.53 (1.01–2.34)* 1.60 (1.05–2.44)* 1.60 (1.05–2.45)*
  Quartile 4 538 79 2.15 (1.45–3.18)** 2.19 (1.48–3.25)** 2.02 (1.35–3.02)**
Prehypertension
 Men
  Quartile 1 241 35 1 (reference) <0.001 1 (reference) <0.001 1 (reference) <0.001
  Quartile 2 234 34 0.91 (0.57–1.46) 0.89 (0.56–1.43) 0.85 (0.53–1.37)
  Quartile 3 239 39 1.14 (0.72–1.80) 1.14 (0.72–1.80) 1.10 (0.69–1.74)
  Quartile 4 235 60 1.70 (1.12–2.58)* 1.78 (1.17–2.71)* 1.42 (0.92–2.18)
 Women
  Quartile 1 205 24 1 (reference) <0.001 1 (reference) <0.001 1 (reference) <0.001
  Quartile 2 204 28 1.16 (0.67–2.00) 1.15 (0.67–1.99) 1.18 (0.68–2.05)
  Quartile 3 207 33 1.26 (0.75–2.13) 1.25 (0.74–2.12) 1.38 (0.81–2.34)
  Quartile 4 201 41 1.67 (1.01–2.77)* 1.70 (1.02–2.82)* 1.63 (0.97–2.73)
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these differences in prevalence may help explain why it 
has been so difficult to even establish the existence of a 
relationship between elevated both pressure and T2DM.
There are limitations to our study that should be dis-
cussed. Firstly, we conducted a post hoc analysis of epide-
miological data collected for other purposes. In addition, 
it is possible that our findings in inhabitants of Korea 
may not apply to other racial/ethnic populations. Thirdly, 
direct quantification of insulin resistance was not avail-
able, and our analysis was based on use of differences in 
dysglycemia, hyperinsulinemia, and dyslipidemia, three 
metabolic abnormalities characteristic of insulin resist-
ance, to evaluate the association between insulin resist-
ance and incident T2DM. Perhaps the most appropriate 
way view our findings is as hypothesis-generating; leaving 
it to future studies to validate, or discard, the formulation 
that the increased incidence of T2DM in patients with 
essential hypertension is related to the increased preva-
lence of insulin resistance in this clinical syndrome.
Conclusion
These data demonstrate that the subset of individuals 
with the greatest degree of insulin resistance, whether 
they have normal blood pressure or prehypertension, 
is at increased risk to develop T2DM. As such, they are 
consistent with the suggestion that it is the increased 
prevalence of insulin resistance in patients with essen-
tial hypertension that accounts for their increased risk 
of T2DM. Put more simply, since prevalence of insulin 
resistance is increased in patients with essential hyper-
tension [5, 28–31], and insulin resistance is a powerful 
predictor of T2DM [3, 4], it should not be surprising, as 
reported by Emdin, et  al. [1], that patients with essen-
tial hypertension are at increased risk to develop T2DM. 
What the current results do is provide evidence that the 
same phenomenon seems to also be true of patients with 
prehypertension.
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